Phase Ib trial of gilteritinib in combination with mitoxantrone, cladribine, cytarabine and filgrastim (GM-CLAG) for relapsed/refractory FLT3-mutated acute myeloid leukemia

Grants and Contracts Details

StatusFinished
Effective start/end date1/17/2210/30/23

Funding

  • Astellas Pharma Global Development Incorporated: $30,000.00